Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

Haematologica

Volumn 96, Issue 9, 2011, Pages 1284-1292

  Bacher, Ulrike ^a   Haferlach, Claudia ^b   Alpermann, Tamara ^b   Kern, Wolfgang ^b   Schnittger, Susanne ^b   Haferlach, Torsten ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute erythroid leukemia; Acute myeloid leukemia; Cytogenetics; Myelodysplastic syndrome; Prognosis

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ERYTHROID LEUKEMIA; ERYTHROID PRECURSOR CELL; FEMALE; GENE MUTATION; GENETIC RISK; GENETICS; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CYTOGENETIC ANALYSIS; ERYTHROID CELLS; ERYTHROPOIESIS; FEMALE; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; YOUNG ADULT;

EID: 80052353729     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.043687     Document Type: Article

References (27)

1. Arber DA, Brunning RD, Orazi A, Porwit A, Peterson L, Thiele J, et al. Acute myeloid leukemia, not otherwise specified. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th ed. Lyon, IARC Press. 2008;130-139.
2. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115(10):1985-1992.
3. Fouillard L, Labopin M, Gorin NC, Polge E, Prentice HG, Meloni, et al. Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2002;100 (9):3135-3140.
4. Arber DA, Brunning RD, Orazi A, Bain BJ, Porwit A, Vardiman JW, et al. Acute myeloid leukaemia with myelodysplasiarelated changes. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th ed. Lyon, IARC Press, 2008;124-126.
5. Swerdlow S, Campo E, Lee Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, IARC press. 2008.
6. Park S, Picard F, Guesnu M, Maloum K, Leblond V, Dreyfus F. Erythroleukaemia and RAEB-t: a same disease? Leukemia. 2004;18(4):888-890.
7. Löffler H, Raststetter J, Haferlach T. Atlas of Clinical Hematology. 6th ed. Berlin, Springer, 2004.
8. Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6(6):520-525.
9. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16(1):53-59.
10. Grimwade D, Hills R, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. 2010;116(3):354-365.
11. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, et al. Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220-2231.
12. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66.
13. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood. 2008;111(5):2527-2537.
14. Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S. Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica. 2005;90(7):881-889.
15. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107(10):3847-3853.
16. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078-3085.
17. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, Ó Brien S, et al. Adult acute erythroleukemia: an analysis of 91patients treated at a single institution. Leukemia. 2009;23(12):2275-2280.
18. Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, et al. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol. 2010;23(8):1113-1126.
19. Domingo-Claros A, Larriba I, Rozman M, Irriguible D, Vallespi T, Aventin A, et al. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica. 2002;87(2):148-1453.
20. Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR. Erythroleukaemia in the north of England: a population based study. J Clin Pathol. 2001;54(8):608-612.
21. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
22. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10): 4011-4020.
23. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-3746.
24. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-3739.
25. Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14(5):796-804.
26. Shiah HS, Kuo YY, Tang JL, Huang SY, Yao M, Tsay W, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia. 2002;16(2):196-202.
27. Wang SA, Tang G, Fadare O, Hao S, Raza A, Woda B, et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008;21(11): 1394-1402.